Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BYSI Stock Forecast 2025-2026
$2.27
Current Price
$89.91M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BYSI Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
BYSI Price Momentum
-6.2%
1 Week Change
+33.5%
1 Month Change
-1.3%
1 Year Change
+39.3%
Year-to-Date Change
-34.0%
From 52W High of $3.44
+131.6%
From 52W Low of $0.98
📊 TOP ANALYST CALLS
Did BYSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Beyondspring is one of their latest high-conviction picks.
Latest BYSI Stock Price Targets & Analyst Predictions
BYSI has shown a year-to-date change of 39.3% and a 1-year change of -1.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BYSI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BYSI Analyst Ratings
2
Buy
0
Hold
0
Sell
BYSI Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.27
Latest BYSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BYSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 2, 2023 | Baird | Joel Beatty | Outperform | Maintains | $1.25 |
| Dec 2, 2021 | Jefferies | Maury Raycroft | Hold | Downgrade | $5.00 |
| Dec 2, 2021 | B of A Securities | Jason Gerberry | Underperform | Downgrade | $5.00 |
| Dec 1, 2021 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Downgrade | $0.00 |
| Sep 20, 2021 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $65.00 |
| Sep 9, 2021 | Baird | Outperform | Initiates | $0.00 | |
| Aug 4, 2021 | HC Wainwright & Co. | Buy | Upgrade | $0.00 | |
| Apr 5, 2021 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 | |
| Jan 11, 2021 | B of A Securities | Buy | Initiates | $0.00 | |
| Dec 29, 2020 | Evercore ISI Group | Outperform | Initiates | $0.00 | |
| Jun 15, 2020 | HC Wainwright & Co. | Buy | Maintains | $46.00 | |
| Mar 30, 2020 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $30.00 |
| Feb 7, 2020 | Jefferies | Buy | Initiates | $0.00 | |
| Jan 10, 2020 | Nomura | Buy | Initiates | $0.00 | |
| Jan 10, 2020 | Nomura Instinet | Buy | Initiates | $0.00 | |
| Dec 3, 2019 | William Blair | Outperform | Initiates | $0.00 | |
| Jun 22, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $48.00 |
| Apr 4, 2017 | Rodman & Renshaw | Buy | Initiates | $0.00 |
BeyondSpring Inc. (BYSI) Competitors
The following stocks are similar to Beyondspring based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BYSI
Beyondspring
mkt cap
89.91M
BeyondSpring Inc. (BYSI) Financial Data
BeyondSpring Inc. has a market capitalization of $89.91M with a P/E ratio of -8.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +77.9%.
Valuation Metrics
Market Cap
$89.91M
Enterprise Value
$102.41M
P/E Ratio
-8.1x
PEG Ratio
-4.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+9.3%
Current Ratio
2.5x
Debt/Equity
0.0x
ROE
+77.9%
ROA
-32.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BeyondSpring Inc. (BYSI) Business Model
About BeyondSpring Inc.
What They Do
Develops innovative cancer therapies.
Business Model
BeyondSpring Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for cancer. The company generates value through its flagship product, Plinabulin, which aims to reduce chemotherapy-induced neutropenia and exhibits anti-cancer properties, potentially addressing unmet needs in oncology.
Additional Information
The company's strategic focus on enhancing treatment efficacy and targeting cancer pathways positions it as a significant player in the biopharmaceutical industry. Investors are particularly attentive to BeyondSpring's advancements, as they may have substantial implications for the future of cancer therapy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Dr. Lan Huang Ph.D.
Country
United States
IPO Year
2017
Website
beyondspringpharma.comBeyondSpring Inc. (BYSI) Latest News & Analysis
Latest News
Quick Summary
BeyondSpring Inc. (NASDAQ: BYSI) presented interim phase 2 data on its 303 Study for NSCLC at the ASCO Annual Meeting, supported by Merck. The study focuses on patients post PD-1/L1 inhibitors.
Why It Matters
The interim phase 2 data on BeyondSpring's NSCLC study could influence stock performance, affecting investor sentiment and potential market valuation, particularly in the oncology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BeyondSpring Inc. (NASDAQ: BYSI) announced its unaudited financial results for Q1 2025 and provided a corporate update, focusing on its development of cancer therapeutics.
Why It Matters
BeyondSpring's quarterly financial results and corporate update signal its current performance and future prospects, impacting stock valuation and investor confidence in its cancer therapeutics pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
BeyondSpring Files 2024 Annual Report on Form 10-K
3 months ago
Quick Summary
BeyondSpring Inc. (NASDAQ: BYSI) filed its annual report on Form 10-K for FY 2024 with the SEC on March 27, 2025, including audited financial statements. Reports are available on SEC and company websites.
Why It Matters
BeyondSpring's 10-K filing reveals its financial health and operational progress, crucial for evaluating investment potential, particularly in the competitive biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SEED Therapeutics received FDA Rare Pediatric Disease and Orphan Drug designations for its ST-01156 molecular glue, targeting RBM39 for solid tumor treatments.
Why It Matters
FDA designations enhance SEED's market potential and attractiveness to investors, signaling a path to expedited development and potential exclusivity for its innovative cancer treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BeyondSpring Inc. (NASDAQ: BYSI) will sell part of its Series A-1 Preferred Shares in SEED Therapeutics for about $35.4 million, retaining approximately 14.4% of SEED's shares post-transaction.
Why It Matters
BeyondSpring's sale of SEED shares for $35.4 million indicates strong capital generation and strategic positioning in cancer therapy, potentially enhancing investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
In a study of 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, a triple IO combo regimen achieved a disease control rate of 89.3% and a median progression-free survival of 8.6 months.
Why It Matters
High DCR and median PFS in a challenging patient group indicate potential for the triple IO combo regimen, potentially boosting the market position of the involved biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BYSI Stock
What is BeyondSpring Inc.'s (BYSI) stock forecast for 2026?
Analyst forecasts for BeyondSpring Inc. (BYSI) are not currently available. The stock is trading at $2.27.
Is BYSI stock a good investment in 2026?
According to current analyst ratings, BYSI has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BYSI stock?
Price predictions from Wall Street analysts for BYSI are not currently available. The stock is trading at $2.27.
What is BeyondSpring Inc.'s business model?
BeyondSpring Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for cancer. The company generates value through its flagship product, Plinabulin, which aims to reduce chemotherapy-induced neutropenia and exhibits anti-cancer properties, potentially addressing unmet needs in oncology.
What is the highest forecasted price for BYSI BeyondSpring Inc.?
Price targets from Wall Street analysts for BYSI are not currently available. The stock is trading at $2.27.
What is the lowest forecasted price for BYSI BeyondSpring Inc.?
Price targets from Wall Street analysts for BYSI are not currently available. The stock is trading at $2.27.
What is the overall BYSI consensus from analysts for BeyondSpring Inc.?
The overall analyst consensus for BYSI is bullish. Out of 6 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are BYSI stock price projections?
Stock price projections, including those for BeyondSpring Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 3:42 AM UTC